A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer (CARTEPC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03013712|
Recruitment Status : Unknown
Verified January 2017 by First Affiliated Hospital of Chengdu Medical College.
Recruitment status was: Recruiting
First Posted : January 6, 2017
Last Update Posted : January 6, 2017
|Condition or disease||Intervention/treatment||Phase|
|Colon Cancer Esophageal Carcinoma Pancreatic Cancer Prostate Cancer Gastric Cancer Hepatic Carcinoma||Biological: CAR-T cell immunotherapy||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer|
|Study Start Date :||January 2017|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2020|
Experimental: CAR-T cell immunotherapy
Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen by infusion.
Biological: CAR-T cell immunotherapy
This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen.
- Toxicity profile of the EpCAM targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0 [ Time Frame: up to 24 months ]Observe and handle the toxicity profile of the EpCAM targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0
- Survival time of anti-EpCAM CAR T cells in vivo [ Time Frame: up to 24 months ]Detect the existence of CAR-T cells in the blood of participants through flow cytometry
- Anti-tumor efficacy of CAR-T therapy by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 [ Time Frame: up to 24 months ]Anti-tumor efficacy of CAR-T therapy for patients with EpCAM positive cancers was assessed by RECIST v1.1
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03013712
|Contact: Yan Zhou, PhDemail@example.com|
|IEC of Chengdu Medical College||Recruiting|
|Chendu, China, 610500|
|Contact: Xiao-an Li, post doctor +8613680868858 firstname.lastname@example.org|
|Study Chair:||Xiao-an Li, PhD||First Affiliated Hospital of Chengdu Medical College|